Pharmacological Facilitation of Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction
Top Cited Papers
- 23 February 2005
- journal article
- review article
- Published by American Medical Association (AMA) in JAMA
- Vol. 293 (8) , 979-986
- https://doi.org/10.1001/jama.293.8.979
Abstract
Current options for reperfusion therapy in patients admitted to a community hospital without cardiac catheterization facilities include administration of fibrinolytic drugs followed by observation, with referral to angiography driven by symptoms and signs of ischemia; transfer to a tertiary care center for primary percutaneous coronary intervention (PCI); or a strategy of facilitated PCI in which administration of fibrinolytics and platelet glycoprotein IIb/IIIa inhibitors (alone or in combination) is followed by transfer for immediate angiography and PCI if appropriate. We systematically analyzed multiple randomized and nonrandomized trials to review the pathophysiology of reperfusion therapy in acute myocardial infarction to derive insights about the likelihood of success of a strategy of facilitated PCI compared with transfer only or fibrinolysis only. The basis for the recommendations made herein is a hypothetical curve relating the duration of symptoms before reperfusion to reduction in mortality and extent of myocardial salvage. During the first 2 to 3 hours after symptom onset, a striking benefit of reperfusion is present; within this period, time to treatment is critical. Subsequently, a mortality benefit is still present but of decreasing magnitude over time. In this situation, the priority is to open the artery, and time to treatment is less critical. Results of facilitated PCI may depend largely on timing of presentation. If presentation is late after symptom onset (ie, on the “flat” part of the curve), there will be little mortality benefit from earlier patency and patients will be subject to the bleeding risks of fibrinolytic drugs. In contrast, among patients presenting very early (60-90 minutes after symptom onset), outcomes with fibrinolytic therapy alone are excellent, and it will be difficult for any other strategy to result in a significant improvement. But in patients presenting 2 to 3 hours after onset of symptoms, a strategy of facilitated PCI may move patients from the plateau to the descending limb of the curve, with a substantial improvement in myocardial salvage and mortality. Two large ongoing trials may provide definitive answers to these issues.Keywords
This publication has 58 references indexed in Scilit:
- Outcomes of Percutaneous Coronary Interventions Performed at Centers Without and With Onsite Coronary Artery Bypass Graft SurgeryPublished by American Medical Association (AMA) ,2004
- Selecting the Best Reperfusion Strategy in ST-Elevation Myocardial InfarctionCirculation, 2003
- Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trialsPublished by Elsevier ,2003
- Rationale for on-site cardiac surgery for primary angioplasty: a time for reappraisalJournal of the American College of Cardiology, 2002
- Predictors of door-to-balloon delay in primary angioplastyThe American Journal of Cardiology, 2002
- The late open artery hypothesis—A decade laterAmerican Heart Journal, 2001
- Early thrombolytic treatment in acute myocardial infarctionThe Lancet, 1996
- Thrombolysis and myocardial salvage. Results of clinical trials and the animal paradigm--paradoxic or predictable?Circulation, 1993
- Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival. Should the paradigm be expanded?Circulation, 1989
- A Randomized Trial of Immediate versus Delayed Elective Angioplasty after Intravenous Tissue Plasminogen Activator in Acute Myocardial InfarctionNew England Journal of Medicine, 1987